[How to manage giant cell arteritis]

Area of Science:

• Rheumatology
• Internal Medicine
• Vasculitis Research

Background:

• Giant cell arteritis (GCA) is the most prevalent vasculitis affecting individuals over 50.
• Prompt corticosteroid treatment is essential to prevent ischemic complications associated with GCA.
• The need for accurate diagnosis is heightened due to the significant side effects of long-term corticosteroid therapy.

Purpose of the Study:

• To review current diagnostic standards for GCA, including imaging and clinical criteria.
• To explore established and emerging therapeutic strategies for managing GCA.
• To discuss the role of tocilizumab, methotrexate, abatacept, and ustekinumab in GCA treatment.

Main Methods:

• Review of histological confirmation as the gold standard for GCA diagnosis.
• Evaluation of non-invasive imaging techniques, particularly temporal artery ultrasound.
• Analysis of clinical studies and regulatory approvals for GCA therapies.

Main Results:

• Temporal artery ultrasound and specific clinical criteria provide reliable non-invasive GCA diagnosis.
• Tocilizumab, in combination with corticosteroids, is approved for GCA treatment.
• Methotrexate has demonstrated efficacy in reducing corticosteroid dosage and relapse rates.

Conclusions:

• Accurate diagnosis of GCA is paramount to guide appropriate and timely treatment.
• Tocilizumab and methotrexate represent significant advancements in GCA management, offering steroid-sparing options.
• Emerging therapies like abatacept and ustekinumab hold promise for future GCA treatment protocols.